Sarepta Therapeutics Inc (NAS:SRPT)
$ 160.77 37.22 (30.14%) Market Cap: 15.20 Bil Enterprise Value: 15.19 Bil PE Ratio: 401.93 PB Ratio: 15.81 GF Score: 82/100

Sarepta Therapeutics Inc Clinical Update: SRP-9003 for Limb-Girdle Muscular Dystrophy Type 2E Conference Call Transcript

Jun 08, 2020 / 12:30PM GMT
Release Date Price: $159.68 (+7.90%)
Operator

Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics' Clinical Update SRP-9003 for Limb-Girdle Muscular Dystrophy Type 2E. (Operator Instructions) As a reminder, today's program is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.

Ian M. Estepan
Sarepta Therapeutics, Inc. - Senior VP of Corporate Affairs & Chief of Staff

Good morning all. Thank you and thank you all for joining today's call. Joining me today are Doug Ingram, Dr. Louise Rodino-Klapac, Dr. Gilmore O'Neill, Sandy Mahatme and Bo Cumbo. After our formal presentation, we'll open up the call for Q&A. I'd like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot